The influence of metformin medication on the blood lipid profile of newly diagnosed type 2 diabetic patients.
The primary goal of this research is to examine the correlation between serum lipid profile of subjects in Jordan who have been diagnosed with type 2 diabetes and are receiving metformin. The present research examined 160 individuals, consisting of 112 men and 48 women (mean age 59.1 ± 8.4). The prescribed medication for each patient with type 2 diabetes mellitus was 500 mg of metformin per day. There are 80 participants in the healthy control group—64 male and 16 female (mean age 57.8 ± 8.9), all of them healthy who did not suffer from any kind of disease. This study found that there are no statistically significant changes in age, body mass index, or blood lipid concentrations among the healthy group and the group of individuals with type 2 diabetes who were newly diagnosed prior to beginning metformin therapy. The fasting blood glucose level (165.4 ± 12.9 mg %) and glycosylated hemoglobin percentage (7.7 ± 0.8 %) were significantly higher in the patients group in comparison with that in the healthy group (90.7 ± 4.1 and 5.3 ± 0.4 %), respectively, p < 0.05). Depending on the findings of this study. Metformin treatment in type 2 diabetes patients can improve the lipid profile concentrations.